Monte Rosa Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Monte Rosa Therapeutics, Inc. (GLUE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.97M, a 21.99% increase year-over-year.
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.95M, a 12.29% increase year-over-year.
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.36M, a 1.91% increase year-over-year.
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.89M, a 8.71% increase year-over-year.
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $18.86M, a 4.08% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $18.13M, a 8.74% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $16.67M, a 42.91% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $11.66M, a 124.31% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.97M 10-Q · filed 2026-08-06 | $11.92M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $5.95M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $18.86M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $4.36M 10-Q · filed 2025-11-06 | $9.26M derived: sum of 2 quarters · filed 2026-08-06 | $14.56M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $4.89M 10-Q · filed 2026-08-06 | $10.19M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $5.30M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $18.13M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $4.28M 10-Q · filed 2025-11-06 | $8.78M derived: sum of 2 quarters · filed 2025-11-06 | $13.66M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $4.50M 10-Q · filed 2025-11-06 | $9.38M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $4.87M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $16.67M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $4.47M 10-Q · filed 2024-11-07 | $8.62M derived: sum of 2 quarters · filed 2024-11-07 | $12.60M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $4.15M 10-Q · filed 2024-11-07 | $8.13M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $3.97M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $11.66M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $3.21M 10-Q · filed 2023-11-09 | $6.09M derived: sum of 2 quarters · filed 2023-11-09 | $8.34M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $2.87M 10-Q · filed 2023-11-09 | $5.12M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $2.25M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $5.20M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $2.07M 10-Q · filed 2022-11-10 | $3.09M derived: sum of 2 quarters · filed 2022-11-10 | $3.34M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.02M 10-Q · filed 2022-11-10 | $1.27M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $252.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $354.00K 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $45.00K 10-Q · filed 2021-11-10 | $142.00K derived: sum of 2 quarters · filed 2021-11-10 | $153.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $97.00K 10-Q · filed 2021-11-10 | $108.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $11.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |